Authored and contributed to PharmaLeaders by Michelle Marlborough, Chief Product Officer, AiCure, LLC Machine learning (ML) innovation for clinical research holds great promise for improving drug development and patient care. But, like with all new technology, increasing prevalence can be accompanied by growing skepticism. Pharmaceutical sponsors and clinicians are understandably suspicious about the value of […]
Featured Article
Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
By Andrea
On May 17th, 500+ of pharma’s clinical innovation will come together for the home of clinical collaboration, Reuters Events: Pharma Clinical 2022, to set new standards in digital and patient innovation for clinical transformation. The catalyst for this has been the accelerated technological adoption in clinical trials, but a general feeling still that enough isn’t […]
White Papers

Mental Health: An Insurance Industry Perspective
How payers look at priorities for care in a time of policy uncertainty and growing concerns in the patient advocacy community. No group of … FREE Download
Schedule Your Personalized Marketing Technology Workshop
PharmaLeaders is pleased to provide our subscribers with a special offer from our webinar partner and presenter, Collaborative Marketing Solutions … FREE Download
Industry News
Quoin Pharmaceuticals signs license, distribution agreement with WinHealth Pharma
This agreement will allow Quoin to offer healthcare professionals and patients in greater China, including Hong Kong, Macau and Taiwan, with access to its products following receipt regulatory The post Quoin Pharmaceuticals signs license, distribution agreement with WinHealth Pharma appeared first … [Read More...]
Rhythm Pharmaceuticals secures FDA approval for sNDA for IMCIVREE to treat BBS
With this FDA approval, IMCIVREE is indicated for chronic weight management in adult and pediatric patients aged six years and older with monogenic or syndromic obesity due to The post Rhythm Pharmaceuticals secures FDA approval for sNDA for IMCIVREE to treat BBS appeared first on Pharmaceutical … [Read More...]
FDA approves Ellipses’ application for advanced RET-altered cancer treatment
EP0031 is a potent next generation selective RET inhibitor (SRI) with broad activity against common RET fusions and mutations, like solvent front resistance mutations. It is jointly developed The post FDA approves Ellipses’ application for advanced RET-altered cancer treatment appeared first on … [Read More...]
FDA approves Novartis’ Tafinlar + Mekinist combination therapy
The combination therapy is indicated to treat unresectable or metastatic solid tumours with the BRAF V600E mutation in adult and paediatric patients aged six years and above whose The post FDA approves Novartis’ Tafinlar + Mekinist combination therapy appeared first on Pharmaceutical Business … [Read More...]